| |
Sincerely, | | | Sincerely, |
| | ||
Ronald W. Hovsepian | | | Ajei S. Gopal |
Chairman of the Board | | | President and Chief Executive Officer |
| |
Sincerely, | | | Sincerely, |
| | ||
Ronald W. Hovsepian | | | Ajei S. Gopal |
Chairman of the Board | | | President and Chief Executive Officer |
1. | to adopt the merger agreement, which proposal is referred to as the “merger agreement proposal”; |
2. | to approve, on a non-binding, advisory basis, the merger-related compensation that will or may be paid to Ansys’ named executive officers in connection with the transactions contemplated by the merger agreement, which proposal is referred to as the “compensation proposal”; and |
3. | to approve the adjournment of the special meeting to solicit additional proxies if there are not sufficient votes at the time of the special meeting to approve the merger agreement proposal or to ensure that any supplement or amendment to the accompanying proxy statement/prospectus is timely provided to Ansys stockholders, which proposal is referred to as the “adjournment proposal.” |
• | the registration statement of which this proxy statement/prospectus is a part becoming effective in accordance with the provisions of the Securities Act of 1933, as amended, no stop order suspending its effectiveness being issued by the United States Securities and Exchange Commission, which is referred to as the “SEC,” and remaining in effect and there being no proceedings for that purpose having been initiated or threatened in writing by the SEC that have not been withdrawn; |
• | the shares of Synopsys common stock to be issued in the merger being approved for listing (subject to official notice of issuance) on the NASDAQ; |
• | the merger agreement being duly adopted at the special meeting by the required Ansys stockholder vote (as defined in the proxy statement/prospectus); |
• | expiration or termination of the waiting period (and any extension thereof) applicable to the completion of the merger under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and any period of time (and any extension thereof) agreed to with a governmental body in the United States not to complete the merger having expired or having been terminated; |
• | the expiration or termination of any waiting period (and any extension thereof) applicable to the completion of the merger under applicable foreign antitrust law or regulation of the specified jurisdictions (as defined in the proxy statement/prospectus), and the expiration or termination of any period of time (and any extension thereof) agreed to with a governmental body in any specified jurisdiction not to complete the merger; |
• | any governmental authorization or other consent required under applicable foreign antitrust law or regulation or foreign investment law in connection with the merger in each specified jurisdiction being obtained and being in full force and effect; and |
• | no temporary restraining order, preliminary or permanent injunction or other order preventing the completion of the merger having been issued by any governmental body in any of the specified jurisdictions and remains in effect, and there having not been any legal requirement enacted or deemed applicable to the merger by any governmental body in any specified jurisdiction that makes completion of the merger illegal. |
• | solicit, initiate, knowingly encourage, assist, induce or facilitate the making, submission or announcement of any offer or proposal (other than an offer or proposal made or submitted by Synopsys) contemplating or otherwise relating to any acquisition transaction (as defined in the proxy statement/prospectus), which is referred to as an “acquisition proposal,” or any inquiry, indication of interest or request for information (other than an inquiry, indication of interest or request for information made or submitted by Synopsys) that would reasonably be expected to lead to an acquisition proposal, which is referred to as an “acquisition inquiry” (including by approving any transaction, or approving any person or entity (other than Synopsys and its affiliates) becoming an “interested stockholder” for purposes of Section 203 of the General Corporation Law of the State of Delaware) or take any action that would reasonably be expected to lead to an acquisition proposal or acquisition inquiry; |
• | furnish or otherwise provide access to any non-public information regarding Ansys or any of its subsidiaries to any person or entity in connection with or in response to an acquisition proposal or acquisition inquiry; |
• | engage in discussions or negotiations with any person or entity with respect to any acquisition proposal or acquisition inquiry (other than to inform such person or entity of the non-solicitation covenants in the merger agreement); |
• | approve, endorse or recommend any acquisition proposal; |
• | enter into any letter of intent, memorandum of understanding, agreement in principle or similar document or any contract relating to, or that contemplates or would reasonably be expected to result in, an acquisition transaction (other than an acceptable confidentiality agreement, as defined in “The Merger Agreement—No Solicitation by Ansys” beginning on page 101); or |
• | resolve or publicly propose to take any of the foregoing actions. |
• | withdraw or modify in a manner adverse to Synopsys, or permit the withdrawal or the modification in a manner adverse to Synopsys of, the Ansys board of directors’ unanimous: (i) determination that the merger agreement and the merger is advisable and fair to and in the best interests of Ansys and its stockholders and (ii) recommendation that Ansys stockholders vote to adopt the merger agreement by voting “FOR” the approval of the merger agreement proposal at the special meeting, which is referred to as the “Ansys board recommendation”; |
• | recommend the approval, acceptance or adoption of, or approve, endorse, accept or adopt, any acquisition proposal; |
• | approve or recommend, or cause or permit Ansys or any of its subsidiaries to execute or enter into, any letter of intent, memorandum of understanding, agreement in principle, merger agreement, acquisition agreement, option agreement, joint venture agreement, partnership agreement or other similar document or contract relating to, or that contemplates or would reasonably be expected to result in, an acquisition transaction (other than an acceptable confidentiality agreement); or |
• | resolve, agree or publicly propose, or permit Ansys or any of its subsidiaries, or any of its or their respective representatives, to agree or publicly propose, to take any of the actions contemplated in any of the preceding bullets. |
• | by the mutual written consent of Synopsys and Ansys; |
• | by either Synopsys and Ansys if the merger has not been completed by 11:59 p.m. (California time) on January 15, 2025, which may be extended to July 15, 2025 and further to January 15, 2026 in certain circumstances in accordance with the terms of the merger agreement, which is referred to as the “end date” (as it may be extended in accordance with the merger agreement) (however, a party is not permitted to terminate the merger agreement on such basis if the failure to complete the merger by the end date is primarily attributable to a failure on the part of such party to perform any covenant or obligation in the merger agreement required to be performed by such party at or prior to the effective time in breach of such party’s obligations); |
• | by either Synopsys or Ansys if: (i) a governmental body in any specified jurisdiction has issued a final and nonappealable order having the effect of permanently restraining, enjoining or otherwise prohibiting the merger; or (ii) there has been any applicable legal requirement enacted, enforced or deemed applicable to the merger by any governmental body in any specified jurisdiction that would make completion of the merger illegal; |
• | by either Synopsys or Ansys upon a no stockholder approval event (as defined in “The Merger Agreement—Termination of the Merger Agreement” beginning on page 117); |
• | by Synopsys (at any time prior to the adoption of the merger agreement by the required Ansys stockholder vote) if a triggering event (as defined in the proxy statement/prospectus) has occurred; |
• | by Ansys (at any time prior to the adoption of the merger agreement by the required Ansys stockholder vote) in order to accept a superior offer and enter into an alternative acquisition agreement (as defined in “The Merger Agreement—Termination of the Merger Agreement” beginning on page 117), subject to compliance with certain obligations under the merger agreement; or |
• | by either Synopsys or Ansys if, subject to certain exceptions, (i) any of the other party’s representations or warranties contained in the merger agreement were inaccurate as of the date of the merger agreement or became inaccurate as of a date subsequent to the date of the merger agreement (as if made on such subsequent date) such that the closing condition relating to the accuracy of such other party’s representations and warranties would not be satisfied; or (ii) any of the other party’s covenants or obligations contained in the merger agreement was breached such that the closing condition relating to the performance by such other party of its covenants would not be satisfied. |
For Information Regarding Synopsys: Synopsys, Inc. 675 Almanor Ave. Sunnyvale, California 94085 (650) 584-5000 Attention: Corporate Secretary | | | For Information Regarding Ansys: ANSYS, Inc. 2600 ANSYS Drive Canonsburg, Pennsylvania 15317 (844) 462-6797 Attention: Corporate Secretary |
• | “acquisition inquiry” refers to an inquiry, indication of interest or request for information (other than an inquiry, indication of interest or request for information made or submitted by Synopsys) that would reasonably be expected to lead to an acquisition proposal; |
• | “acquisition proposal” refers to any offer or proposal (other than an offer or proposal made or submitted by Synopsys) contemplating or otherwise relating to any acquisition transaction; |
• | “acquisition transaction” refers to any transaction or series of related transactions (other than the transactions contemplated by the merger agreement) involving: |
○ | any merger, consolidation, amalgamation, plan or scheme of arrangement, share exchange, business combination, joint venture, reorganization, recapitalization, tender offer, exchange offer or other similar transaction involving Ansys, except for any such transaction in which the Ansys stockholders immediately preceding such transaction continue to hold immediately following such transaction, directly or indirectly, 85% or more of the equity interests in the surviving or resulting entity in such transaction (whether by voting power or number of shares); |
○ | any issuance of securities, acquisition of securities or other transaction: (a) in which a person, entity or “group” (as defined in the Exchange Act and the rules promulgated thereunder) of persons or entities directly or indirectly acquires beneficial or record ownership of securities representing 15% or more of the outstanding securities of any class (or instruments convertible into or exercisable or exchangeable for 15% or more of any such class) of Ansys; or (b) in which Ansys issues securities representing 15% or more of the outstanding securities of any class (or instruments convertible into or exercisable or exchangeable for 15% or more of any such class) of Ansys; or |
○ | any sale, lease, exchange, transfer, license, sublicense or disposition by Ansys or any of its subsidiaries to any person, entity or “group” (as defined in the Exchange Act and the rules |
• | “adjournment proposal” refers to the proposal for Ansys stockholders to approve the adjournment of the Ansys special meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Ansys special meeting to approve the merger agreement proposal or to ensure that any supplement or amendment to this proxy statement/prospectus is timely provided to Ansys stockholders; |
• | “Ansys” means ANSYS, Inc., a Delaware corporation |
• | “Ansys board of directors” refers to the board of directors of Ansys; |
• | “Ansys board recommendation” refers to the Ansys board of directors’ unanimous: (i) determination that the merger agreement and the merger is advisable and fair to and in the best interests of Ansys and its stockholders and (ii) recommendation that Ansys stockholders vote to adopt the merger agreement by voting “FOR” the approval of the merger agreement proposal at the special meeting; |
• | “Ansys bylaws” refers to the Fifth Amended and Restated By-Laws of Ansys; |
• | “Ansys charter” refers to the Restated Certificate of Incorporation of Ansys; |
• | “Ansys common stock” refers to the common stock, $0.01 par value per share, of Ansys; |
• | “Ansys credit agreement” refers to that certain credit agreement, dated as of June 30, 2022 (as amended by Amendment No. 1 to Credit Agreement, dated as of September 29, 2023), among Ansys, as Borrower, the Designated Borrowers from time to time party thereto, each Lender from time to time party thereto, PNC Bank, National Association, as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other L/C Issuers from time to time party thereto; |
• | “Ansys excluded shares” refers to, collectively, (i) shares of Ansys common stock owned by Ansys (or in Ansys’ treasury), Synopsys or any of their respective wholly-owned subsidiaries immediately prior to the effective time and (ii) shares of Ansys common stock held by a holder who has made a proper demand for appraisal of such shares in accordance with Section 262 of the DGCL and not validly withdrawn such demand or otherwise lost their rights of appraisal with respect to such shares pursuant to Section 262 of the DGCL; |
• | “Ansys equity plans” refers to, collectively, the 2021 Equity and Incentive Compensation Plan, the Fourth Amended and Restated 1996 Stock Option and Grant Plan and the Fifth Amended and Restated 1996 Stock Option and Grant Plan; |
• | “Ansys PSUs” refers to Ansys RSUs that vest on the basis of time and the achievement of performance targets and pursuant to which the holder has a right to receive shares of Ansys common stock or cash following the vesting or lapse of restrictions applicable to such performance stock unit; |
• | “Ansys RSUs” refers to Ansys restricted stock units; |
• | “Ansys stockholders” refers to holders of Ansys common stock; |
• | “assumed shares” refers to shares of Synopsys common stock resulting from the conversion of residual shares remaining available for issuance under the Ansys equity plans at the effective time; |
• | “capital markets issuance” refers to any of the following, the use of proceeds of which are for the satisfaction of all of Synopsys’ payment obligations under the merger agreement due at the closing: one or more issuances of non-convertible and non-exchangeable debt securities in an offering, which may consist of multiple tranches, registered under the Securities Act or in a private placement pursuant to an exemption from the registration requirements of the Securities Act; |
• | “closing” refers to the completion of the merger and the other contemplated transactions; |
• | “closing date” refers to the date on which the closing occurs; |
• | “Code” refers to the Internal Revenue Code of 1986, as amended; |
• | “combined company” refers to Synopsys immediately following the completion of the merger and the other transactions contemplated by the merger agreement; |
• | “commitment parties” refers, collectively, to Bank of America, N.A., BofA Securities, Inc., HSBC Securities (USA) Inc., HSBC Bank USA, National Association, The Hongkong and Shanghai Banking Corporation Limited and JPMorgan Chase Bank, N.A.; |
• | “compensation proposal” refers to the proposal for Ansys stockholders to approve on a non-binding advisory basis, the merger-related executive officer compensation payments that will or may be paid by Ansys to its named executive officers in connection with the merger; |
• | “confidentiality agreement” refers to the confidentiality agreement by and between Ansys and Synopsys with respect to the transaction; |
• | “conversion ratio” refers to an amount equal to the sum of the exchange ratio plus the quotient (rounded down to four decimal places) obtained by dividing the per share cash amount by the Synopsys measurement price; |
• | “converted options” refers to each Ansys option (other than (i) a specified option or (ii) an out-of-the-money option held by a person or entity who, as of immediately prior to the effective time, is no longer an employee or other service provider to Ansys or any of its subsidiaries) that is assumed by Synopsys and converted into an option to purchase on the same terms and conditions as were applicable under such Ansys option, a certain number of shares of Synopsys common stock; |
• | “converted RSUs” refers to Ansys RSUs outstanding and unvested immediately prior to the effective time and that are not specified RSUs; |
• | “Court of Chancery” refers to the Court of Chancery of the State of Delaware; |
• | “debt commitment letter” refers to the commitment letter, dated as of January 15, 2024, by and among Synopsys and the commitment parties, as it may be amended from time to time; |
• | “DGCL” refers to the General Corporation Law of the State of Delaware; |
• | “DOJ” refers to the U.S. Department of Justice; |
• | “effective time” refers to the date and time when the merger becomes effective under the DGCL, which will be the date and time at which the certificate of merger with respect to the merger is filed with the Secretary of State of the State of Delaware, or such later date and time as maybe mutually agreed to by Synopsys and Ansys and specified in the certificate of merger; |
• | “end date” refers to January 15, 2025, which may be extended to July 15, 2025 and further to January 15, 2026 in certain circumstances in accordance with the terms of the merger agreement; |
• | “equity award cash consideration amount” refers to an amount in cash equal to the sum of the per share cash amount plus the product of (i) the exchange ratio multiplied by (ii) the Synopsys measurement price; |
• | “ESPP” refers to the Ansys 2022 Employee Stock Purchase Plan, as amended; |
• | “Exchange Act” refers to the Securities Exchange Act of 1934, as amended; |
• | “exchange ratio” refers to 0.3450, which reflects the number of shares of Synopsys common stock that Ansys stockholders will be entitled to receive in the merger for each issued and outstanding share of Ansys common stock held immediately prior to the effective time pursuant to, and in accordance with, the terms of the merger agreement; |
• | “exchange ratio reduction amount” refers to the minimum amount of reduction in the exchange ratio necessary (rounded down to four decimal places) such that the aggregate number of shares of Synopsys |
• | “FTC” refers to the U.S. Federal Trade Commission; |
• | “GAAP” refers to U.S. generally accepted accounting principles; |
• | “HSR Act” refers to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended; |
• | “in-the-money option” means an option to purchase shares of Ansys common stock that is unexpired, unexercised and outstanding immediately prior to the effective time and has a per share exercise price for the Ansys common stock subject to such option that is less than the equity award cash consideration amount; |
• | “maximum share number” refers to 19.9999% of the issued and outstanding shares of Synopsys common stock immediately prior to the effective time; |
• | “merger” refers to the merger of Merger Sub with and into Ansys; |
• | “merger agreement” refers to that certain Agreement and Plan of Merger, dated as of January 15, 2024, by and among Synopsys, Merger Sub and Ansys, as it may be amended from time to time; |
• | “merger agreement proposal” refers to the proposal for the Ansys stockholders to adopt the merger agreement; |
• | “merger consideration” refers to (i) 0.3450 of a share of Synopsys common stock and $197.00 in cash, without interest; (ii) any cash in lieu of fractional shares of shares of Synopsys common stock that a holder of Ansys common stock is entitled to receive pursuant to the merger agreement; and (iii) any dividends or other distributions that a holder of Ansys common stock is entitled to receive with respect to a share of Ansys common stock pursuant to the merger agreement, collectively, which each share of Ansys common stock that is outstanding immediately prior to the effective time (other than Ansys excluded shares) will be converted into the right to receive pursuant to, and in accordance with, the terms of the merger agreement; |
• | “Merger Sub” refers to ALTA Acquisition Corp.; |
• | “NASDAQ” refers to the Nasdaq Global Select Market; |
• | “out-of-the-money option” refers to an option to purchase shares of Ansys common stock that is unexpired, unexercised and outstanding immediately prior to the effective time and which has a per share exercise price for the Ansys common stock subject to such option that is equal to or greater than the equity award cash consideration amount; |
• | “per share cash amount” refers to $197.00 in cash, without interest; |
• | “pre-closing period” refers to the period from the date of the merger agreement and the earlier to occur of (i) the effective time and (ii) the valid termination of the merger agreement pursuant to its terms; |
• | “required Ansys stockholder vote” refers to the affirmative vote of the holders of a majority of the shares of Ansys common stock outstanding on the record date for the special meeting; |
• | “revolving credit facility” refers to the amended and restated credit agreement, dated as of February 13, 2024, as it may be further amended, by and among Synopsys, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent; |
• | “second request” refers to a Request for Additional Information and Documentary Material issued by the Antitrust Division of the DOJ or the FTC; |
• | “Securities Act” refers to the Securities Act of 1933, as amended; |
• | “specified option” refers to each in-the-money option that is vested or unvested that is held by a person who, as of immediately prior to the effective time, is no longer an employee or other service provider of Ansys or its subsidiaries; |
• | “specified RSU” refers to each Ansys RSU that (i) is vested but not yet settled as of immediately prior to the effective time, (ii) is outstanding as of immediately prior to the effective time and was granted to a non-employee member of Ansys’ board of directors, (iii) vests effective as of the effective time in accordance with its terms, or (iv) is outstanding and not forfeited in accordance with its terms immediately prior to the effective time and held by a person who, as of immediately prior to the effective time, is no longer an employee or other service provider to Ansys or its subsidiaries; |
• | “superior offer” refers to a bona fide, written acquisition proposal submitted to Ansys after the date of the merger agreement that is on terms and conditions that the Ansys board of directors determines in good faith, after having taken into account the advice of an independent financial advisor of nationally recognized reputation and Ansys’ outside legal counsel and the likelihood and timing of completion of the acquisition transaction contemplated by such acquisition proposal, to be more favorable to Ansys’ stockholders than the merger. For purposes of the reference to an “acquisition proposal” in this definition, all references to “15%” and “85%” in the definition of “acquisition transaction” will be deemed to refer to “50%”; |
• | “surviving corporation” refers to Ansys, following completion of the merger, as a wholly owned subsidiary of Synopsys; |
• | “Synopsys” refers to Synopsys, Inc., a Delaware corporation; |
• | “Synopsys board of directors” refers to the board of directors of Synopsys; |
• | “Synopsys bylaws” refers to the Amended and Restated Bylaws of Synopsys; |
• | “Synopsys charter” refers to the Restated Certificate of Incorporation of Synopsys; |
• | “Synopsys common stock” refers to the common stock, $0.01 par value per share, of Synopsys; |
• | “Synopsys measurement price” refers to the volume weighted average trading price of Synopsys common stock for the five consecutive trading days ending on the trading day immediately prior to the date on which the effective time occurs; |
• | “Synopsys RSUs” refers to Synopsys restricted stock units; |
• | “term loan credit agreement” refers to the term loan facility credit agreement, dated as of February 13, 2024, by and among Synopsys, as borrower, JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto; and |
• | A “triggering event” is deemed to have occurred if (i) the Ansys board of directors or any committee thereof has: (a) withdrawn the Ansys board recommendation; (b) modified the Ansys board recommendation in a manner adverse to Synopsys; or (c) taken, authorized or publicly proposed any of the prohibited board actions (as defined in “The Merger Agreement—Ansys Stockholder Meeting; Ansys Board Recommendation” beginning on page 103); (ii) Ansys has failed to include the Ansys board recommendation in this proxy statement/prospectus; (iii) Synopsys has requested, after an acquisition proposal has been publicly disclosed, commenced, announced or made, that the Ansys board recommendation be reaffirmed publicly, and the Ansys board of directors has failed to reaffirm, unanimously and publicly, the Ansys board recommendation within 10 business days after such request was made (or, if earlier, prior to the special meeting); (iv) a tender or exchange offer relating to shares Ansys common stock has commenced and Ansys has not sent to its securityholders, within 10 business days after the commencement of such tender or exchange offer, if such offer has not been withdrawn prior to the end of such 10 business day period (or, if earlier, prior to the special meeting), a statement disclosing that Ansys recommends rejection of such tender or exchange offer and reaffirming the board recommendation; (v) Ansys has called or convened a meeting of the Ansys stockholders to consider an acquisition proposal or has failed to convene or hold the special meeting in accordance with certain provisions of the merger agreement; or (vi) Ansys or any of its subsidiaries or any representative of Ansys or any of its subsidiaries has breached (or be deemed to have breached) any of the no-shop covenants (as defined in “The Merger Agreement—No Solicitation by Ansys” beginning on page 101) or the board recommendation covenants (as defined in “The Merger Agreement—Ansys Stockholder Meeting; Ansys Board Recommendation” beginning on page 103) in any material respect. |
Q: | Why am I receiving this proxy statement/prospectus? |
A: | You are receiving this proxy statement/prospectus because Synopsys has agreed to acquire Ansys through a merger of Merger Sub with and into Ansys, with Ansys surviving the merger as a wholly owned subsidiary of Synopsys. The merger agreement governs the terms of the merger and is attached to this proxy statement/prospectus as Annex A. |
Q: | When and where will the special meeting take place? |
A: | The special meeting will be held virtually via the special meeting website, on May 22, 2024, at 11:00 a.m., Eastern Time. |
Q: | Does my vote matter? |
A: | Yes, your vote is very important, regardless of the number of shares that you own. The merger cannot be completed unless the merger agreement is adopted by Ansys stockholders. |
Q: | What will I receive if the merger is completed? |
A: | If the merger is completed, each share of Ansys common stock outstanding as of immediately prior to the effective time (other than Ansys excluded shares) will be converted into the right to receive (a) $197.00 in cash, without interest, and (b) 0.3450 of a share of Synopsys common stock. No fractional shares of Synopsys common stock will be issued upon the conversion of shares of Ansys common stock pursuant to the merger agreement. Each holder of shares of Ansys common stock who would otherwise have been |
Q: | Will Ansys equity awards be affected by the merger? |
A: | Ansys Options |
Q: | What will happen to the Ansys 2022 Employee Stock Purchase Plan? |
A: | For the ESPP, Ansys will take action to provide that: (i) no new offering period (or similar period during which shares may be purchased) will commence under the ESPP following the date of the merger agreement; (ii) participants in the ESPP may not increase their payroll deductions from those in effect on the date of the merger agreement; and (iii) no new participants may commence participation in the ESPP following the date of the merger agreement. In addition, prior to the effective time, Ansys will take all actions necessary to: (a) cause any offering period (or similar period during which shares may be purchased) in progress as of the date of the merger agreement to be the final offering period under the ESPP and to be terminated no later than five business days prior to the date on which the effective time occurs; (b) make any pro-rata adjustments that may be necessary to reflect the shortened offering period (or similar period), but otherwise treat such shortened offering period (or similar period) as a fully effective and completed offering period for all purposes under the ESPP; (c) cause each participant’s then-outstanding share purchase right under the ESPP to be exercised as of no later than two business days prior to the date on which the effective time occurs (referred to herein as the “final exercise date”); and (d) terminate the ESPP as of, and subject to the occurrence of, the effective time. On the final exercise date, funds credited as of such date under the ESPP within the associated accumulated payroll withholding account for each participant under the ESPP will be used to purchase shares of Ansys common stock in accordance with the terms of the ESPP (as amended pursuant to the foregoing), and each share purchased immediately prior to the effective time will be canceled at the effective time and converted into the right to receive the merger consideration in accordance with the terms of the merger agreement, subject to withholding of any applicable income and employment withholding taxes. Any accumulated contributions of each participant under the ESPP as of immediately prior to the effective time will, to the extent not used to purchase shares under the ESPP, be refunded to such participant as promptly as practicable following the final exercise date (without interest). |
Q: | How does the Ansys board of directors recommend that I vote at the special meeting? |
A: | The Ansys board of directors unanimously recommends that you vote “FOR” the merger agreement proposal, “FOR” the compensation proposal and “FOR” the adjournment proposal. |
Q: | Who is entitled to vote at the special meeting? |
A: | The record date for the special meeting is April 9, 2024, which is referred to as the “record date.” All holders of shares of Ansys common stock who held shares at the close of business on the record date are entitled to receive notice of, and to vote at, the special meeting. Each such holder of Ansys common stock is entitled to cast one vote on each matter properly brought before the special meeting for each share of Ansys common stock that such holder owned of record as of the record date. Attendance at the special meeting via the special meeting website is not required to vote. See below and the section entitled “The Special Meeting—Methods of Voting” beginning on page 45 for instructions on how to vote your shares without attending the special meeting. |
Q: | What is a proxy? |
A: | A stockholder’s legal designation of another person to vote shares of such stockholder’s common stock at a special meeting is referred to as a proxy. The document used to designate a proxy to vote your shares of Ansys common stock is referred to as a proxy card. |
Q: | How many votes do I have for the special meeting? |
A: | Each Ansys stockholder is entitled to one vote for each share of Ansys common stock held of record as of the close of business on the record date. As of the close of business on the record date, there were 87,299,981 outstanding shares of Ansys common stock. |
Q: | What constitutes a quorum for the special meeting? |
A: | The holders of a majority of the shares of Ansys common stock entitled to vote at the special meeting must be present or represented at the special meeting by proxy in order to constitute a quorum. |
Q: | Will the Synopsys common stock that I receive in the merger be publicly traded? |
A: | Yes. The shares of Synopsys common stock to be issued in the merger will be listed for trading on the NASDAQ under the symbol “SNPS.” |
Q: | What happens if the merger is not completed? |
A: | If the merger agreement is not adopted by Ansys stockholders or if the merger is not completed for any other reason, Ansys stockholders will not receive any merger consideration for their shares of Ansys common stock in connection with the merger. Instead, Ansys will remain an independent public company and Ansys common stock will continue to be listed and traded on the NASDAQ. If the merger agreement is terminated under specified circumstances, either Ansys or Synopsys may be required to pay the other party a termination fee. See the section entitled “The Merger Agreement—Transaction Expenses and Termination Fees” beginning on page 119 for a more detailed discussion of the respective termination fees. |
Q: | Will the merger affect the board of directors of Synopsys after the merger? |
A: | Yes. At the effective time, two members of the Ansys board of directors selected by mutual agreement of Synopsys and Ansys will be appointed to the Synopsys board of directors. On March 19, 2024, Synopsys |
Q: | What is a “broker non-vote”? |
A: | Under the NASDAQ rules, banks, brokers and other nominees may use their discretion to vote “uninstructed” shares (i.e., shares of record held by banks, brokers or other nominees, but with respect to which the beneficial owner of such shares has not provided instructions on how to vote on a particular proposal) with respect to matters that are considered to be “routine,” but not with respect to “non-routine” matters. All the proposals currently scheduled for consideration at the special meeting are “non-routine” matters. |
Q: | What stockholder vote is required for the approval of each proposal at the special meeting? What will happen if I fail to vote or abstain from voting on each proposal at the special meeting? |
A: | Proposal 1: Merger agreement proposal. The adoption of the merger agreement by Ansys stockholders requires the affirmative vote of a majority of the outstanding shares of Ansys common stock entitled to vote thereon. Accordingly, an Ansys stockholder’s abstention from voting, a broker non-vote or the failure of an Ansys stockholder to vote (including the failure of an Ansys stockholder who holds shares in “street name” through a bank, broker or other nominee to give voting instructions to that bank, broker or other nominee) will have the same effect as a vote “AGAINST” the merger agreement proposal. |
Q: | Why am I being asked to consider and vote on a proposal to approve, by non-binding, advisory vote, merger-related compensation arrangements for Ansys’ named executive officers referred to as the compensation proposal? |
A: | Under the SEC rules, Ansys is required to seek a non-binding, advisory vote of its stockholders with respect to the compensation that may be paid or become payable to Ansys’ named executive officers that is based on or otherwise relates to the merger, also known as “golden parachute” compensation. |
Q: | What happens if Ansys stockholders do not approve, by non-binding, advisory vote, the compensation proposal? |
A: | The vote on the proposal to approve the merger-related compensation arrangements for Ansys’ named executive officers is separate and apart from the votes to approve the other proposals being presented at the special meeting. Because the vote on the proposal to approve the merger-related executive compensation is advisory in nature only, it will not be binding upon Synopsys or Ansys. Accordingly, the merger-related compensation will be paid to Ansys’ named executive officers to the extent payable in accordance with the terms of their compensation agreements and arrangements even if Ansys’ stockholders do not approve the proposal to approve the merger-related compensation. |
Q: | How can I vote my shares at the special meeting? |
A: | Record Holders. Shares held directly in your name as the holder of record of Ansys common stock may be voted at the special meeting. If you choose to vote your shares virtually at the special meeting via the special meeting website, please follow the instructions on your proxy card. |
Q: | How can I vote my shares without attending the special meeting? |
A: | Whether you hold your shares directly as the stockholder of record of Ansys or beneficially in “street name,” you may direct your vote by proxy without attending the special meeting via the special meeting website. You can vote by proxy over the Internet, or by telephone or by mail by following the instructions provided in the enclosed proxy card. Please note that if you hold shares beneficially in “street name,” you should follow the voting instructions provided by your bank, broker or other nominee. |
Q: | What is the difference between holding shares as a stockholder of record and as a beneficial owner of shares held in “street name?” |
A: | If your shares of common stock in Ansys are registered directly in your name with American Stock Transfer & Trust Company, Ansys’ transfer agent, you are considered the stockholder of record with respect to those shares. As the stockholder of record, you have the right to vote, or to grant a proxy for your vote directly to Ansys or to a third party to vote, at the special meeting. |
Q: | If my shares of Ansys common stock are held in “street name” by my bank, broker or other nominee, will my bank, broker or other nominee automatically vote those shares for me? |
A: | No. Your bank, broker or other nominee will only be permitted to vote your shares of Ansys common stock if you instruct your bank, broker or other nominee how to vote. You should follow the procedures provided |
Q: | What should I do if I receive more than one set of voting materials for the same special meeting? |
A: | If you hold shares of Ansys common stock in “street name” and also directly in your name as a stockholder of record or otherwise, or if you hold shares of Ansys common stock in more than one brokerage account, you may receive more than one set of voting materials relating to the same special meeting. |
Q: | If a stockholder submits a proxy, how are the shares of Ansys common stock voted? |
A: | Regardless of the method you choose to vote, the individuals named on the enclosed proxy card will vote your shares of Ansys common stock in the way that you indicate. When completing the Internet or telephone voting processes or the proxy card, you may specify whether your shares of Ansys common stock should be voted for or against, or abstain from voting on, all, some or none of the specific items of business to come before the special meeting. |
Q: | How will my shares of Ansys common stock be voted if I return a blank proxy? |
A: | If you sign, date and return your proxy card and do not indicate how you want your shares of Ansys common stock to be voted, then your shares of Ansys common stock will be voted in accordance with the recommendation of the Ansys’ board of directors and “FOR” the merger agreement proposal, “FOR” the compensation proposal and “FOR” the adjournment proposal. |
Q: | Can I change my vote after I have submitted my proxy? |
A: | Any stockholder submitting a proxy has the right to revoke it before the proxy is voted at the special meeting by doing any of the following: |
• | sending a signed written notice of revocation to Ansys’ corporate secretary; |
• | voting again by the Internet or telephone at a later time before the closing of the voting facilities at 11:59 p.m., Eastern Time, on the date before the special meeting; |
• | submitting a properly signed proxy card with a later date; or |
• | attending virtually and voting at the special meeting via the special meeting website. |
Q: | If I hold my shares in “street name,” can I change my voting instructions after I have submitted voting instructions to my bank, broker or other nominee? |
A: | If your shares are held in the name of a bank, broker or other nominee and you previously provided voting instructions to your bank, broker or other nominee, you should follow the instructions provided by your bank, broker or other nominee to revoke or change your voting instructions. |
Q: | Where can I find the voting results of the special meeting? |
A: | The preliminary voting results for the special meeting will be announced at the special meeting. In addition, within four business days following certification of the final voting results, Ansys will file the final voting results of its special meeting with the SEC on a Current Report on Form 8-K. |
Q: | If I do not favor the merger, what are my rights? |
A: | If you are not in favor of the merger, you may vote your shares of Ansys common stock against the merger agreement proposal. Information about how Ansys stockholders may vote on the proposals being considered in connection with the merger can be found under the section entitled “The Special Meeting” beginning on page 43. |
Q: | Are there any risks that I should consider in deciding whether to vote for the approval of the merger agreement proposal? |
A: | Yes. You should read and carefully consider the risk factors set forth in the section entitled “Risk Factors” beginning on page 27. You also should read and carefully consider the risk factors of Synopsys and Ansys contained in the documents that are incorporated by reference into this proxy statement/prospectus. |
Q: | What happens if I sell my shares of Ansys common stock after the record date but before the special meeting? |
A: | The record date is earlier than the date of the special meeting. If you transfer your shares of Ansys common stock after the record date but before the special meeting, you will, unless special arrangements are made, retain your right to vote at the special meeting. |
Q: | Should I send in my stock certificates now? |
A: | No. Please do not send in your stock certificates with your proxy. After the merger is completed, an exchange agent designated by Synopsys (which will be Synopsys’ transfer agent or another bank or trust company reasonably acceptable to Ansys), which is referred to as the exchange agent, will send you instructions for exchanging Ansys stock certificates for the consideration to be received in the merger. See the section entitled “The Merger Agreement—Exchange Procedures” beginning on page 93. |
Q: | Who will solicit and pay the cost of soliciting proxies? |
A: | Ansys has engaged Mackenzie Partners, Inc., which is referred to as Mackenzie, to assist in the solicitation of proxies for the special meeting. Ansys estimates that it will pay Mackenzie a fee of approximately $75,000, plus reimbursement for certain fees and expenses. Ansys has agreed to indemnify Mackenzie against various liabilities and expenses that relate to or arise out of its solicitation of proxies (subject to certain exceptions). Ansys also may be required to reimburse banks, brokers and other custodians, nominees |
Q: | What are the United States federal income tax consequences of the merger to U.S. holders of Ansys common stock? |
A: | The receipt of the merger consideration in exchange for shares of Ansys common stock pursuant to the merger will be a taxable transaction for U.S. federal income tax purposes. Accordingly, U.S. holders (as defined below in the section entitled “U.S. Federal Income Tax Consequences of the Merger,” beginning on page 147) generally will recognize gain or loss equal to the difference between (i) the sum of the cash and the fair market value (as of the effective time) of the stock consideration they receive in the merger and (ii) their adjusted tax basis in Ansys common stock surrendered in exchange therefor. See the section entitled “U.S. Federal Income Tax Consequences of the Merger” for more information. You should be aware that the tax consequences to you of the merger may depend upon your own situation. In addition, you may be subject to U.S. federal, state, local and non-U.S. tax laws that are not discussed in this proxy statement/prospectus. You should therefore consult with your own tax advisor(s) for a full understanding of the tax consequences to you of the merger. |
Q: | When is the merger expected to be completed? |
A: | Subject to the satisfaction or waiver of the closing conditions described under the section entitled “The Merger Agreement—Conditions to the Completion of the Merger” beginning on page 114, including the adoption of the merger agreement by Ansys stockholders, the merger is expected to be completed in the first half of 2025. However, neither Ansys nor Synopsys can predict the actual date on which the merger will be completed, or if the merger will be completed at all, because completion of the merger is subject to conditions and factors outside the control of both companies. Synopsys and Ansys hope to complete the merger as soon as reasonably practicable. See also the section entitled “The Merger—Regulatory Approvals and Related Matters” beginning on page 85. |
Q: | What are the conditions to completion of the merger? |
A: | The merger is subject to a number of conditions to closing as specified in the merger agreement. These closing conditions include, among others, (i) the adoption of the merger agreement by the holders of a majority of the outstanding shares of Ansys common stock, (ii) the expiration or early termination of the applicable waiting period under the HSR Act and the approval of the merger under certain other antitrust and foreign investment regimes, (iii) the absence of any order, injunction, ruling issued by any governmental body in the United States or certain other jurisdictions preventing the completion of the merger that remains in effect, or legal requirement enacted or deemed applicable by a governmental body in certain jurisdictions making the completion of the merger illegal, (iv) the effectiveness of the registration statement of Synopsys pursuant to which shares of Synopsys common stock to be issued in the merger will be registered with the SEC and the absence of any stop order or proceedings by the SEC with respect thereto, (v) the shares of Synopsys common stock to be issued in the merger being approved for listing on the NASDAQ, (vi) the accuracy of certain representations and warranties of the other party and the compliance by such other party with certain of its covenants, in each case, subject to the materiality standards set forth in the merger agreement and (vii) the absence of a material adverse effect with respect to Synopsys or Ansys after the date of the merger agreement that is continuing. No assurance can be given that the required stockholder, governmental and regulatory consents and approvals will be obtained or that the required conditions to closing will be satisfied, and, even if all required consents and approvals are obtained and the conditions are satisfied, no assurance can be given as to the terms, conditions and timing of such consents and approvals. Any delay in completing the merger could cause Synopsys not to realize, or to be delayed in realizing, some or all the benefits that Synopsys and Ansys expect to achieve if the merger is successfully completed within its expected time frame. For a more complete summary of the conditions that must be satisfied or waived before completion of the merger, see the section entitled “The Merger Agreement—Conditions to the Completion of the Merger” beginning on page 114. |
Q: | What equity stakes will Ansys stockholders hold in Synopsys immediately following the merger? |
A: | Upon completion of the merger, Ansys stockholders are expected to hold approximately 16.5% of the issued and outstanding shares of the combined company immediately following the completion of the merger. The exact equity stake of Ansys stockholders in the combined company immediately following the merger will depend on the number of shares of Synopsys common stock and Ansys common stock issued and outstanding immediately before the merger. |
Q: | If I am an Ansys stockholder and I have not demanded my appraisal rights, how will I receive the merger consideration to which I am entitled? |
A: | If you hold your shares of Ansys common stock through The Depository Trust Company, which is referred to as DTC, in book-entry form and you have not demanded your appraisal rights (more information on appraisal rights may be found in the section entitled “Appraisal Rights” beginning on page 157), you will not be required to take any specific actions to exchange your shares for the merger consideration. After the completion of the merger, shares of Ansys common stock held through DTC in book-entry form will be automatically exchanged for the cash consideration and for shares of Synopsys common stock in book-entry form and cash to be paid in lieu of any fractional share of Synopsys common stock to which you are entitled. If you hold your shares of Ansys common stock in certificated form, or in book-entry form but not through DTC, after receiving the proper documentation from you, following the effective time, the exchange agent will deliver to you the cash consideration, the Synopsys common stock (in book-entry form) and cash in lieu of fractional shares to which you are entitled. More information may be found in the sections entitled “The Merger—Exchange of Shares and Payment Procedures” beginning on page 87 and “The Merger Agreement—Exchange Procedures” beginning on page 93. |
Q: | What should I do now? |
A: | You should read this proxy statement/prospectus carefully and in its entirety, including the annexes, and return your completed, signed and dated proxy card by mail in the enclosed postage-paid envelope or submit your voting instructions by telephone or over the Internet as soon as possible so that your shares will be voted in accordance with your instructions. |
Q: | Whom do I call if I have questions about the special meeting or the merger? |
A: | If you have questions about the special meeting or the merger, or desire additional copies of this proxy statement/prospectus or additional proxies, you may contact Ansys’ proxy solicitor: |
• | at the effective time, each Ansys equity award held by a director or executive officer will receive the treatment described in the section entitled “The Merger Agreement—Treatment of Ansys Equity Awards”; |
• | eligibility of Ansys’ executive officers to receive severance payments and benefits (including equity award vesting acceleration) either under their employment agreement with Ansys or under an Ansys executive severance plan or award agreement, as described in more detail in the section of this proxy statement captioned “The Merger—Interests of Ansys’ Directors and Executive Officers in the Merger—Potential Severance Payments Upon a Qualifying Termination Prior to or Following the Effective Time”; |
• | receipt by each non-employee member of the Ansys board of directors of a one-time cash payment of $35,000 and a monthly cash payment in the amount of $15,000 for the period commencing in September 2023 and through and including the earlier to occur of the month in which the effective time occurs and the month in which the merger agreement is terminated in accordance with its terms, as described in more detail in the section of this proxy statement captioned “The Merger—Interests of Ansys’ Directors and Executive Officers in the Merger—Non-Employee Director Compensation”; |
• | appointment to the Synopsys board of directors of two members of the Ansys board of directors who are mutually agreed between Ansys and Synopsys; and |
• | continued indemnification and directors’ and officers’ liability insurance to be provided by the surviving corporation. |
• | the registration statement of which this proxy statement/prospectus is a part becoming effective in accordance with the provisions of the Securities Act, no stop order suspending its effectiveness being issued by the SEC and remaining in effect and there being no proceedings for that purpose having been initiated or threatened in writing by the SEC that have not been withdrawn; |
• | the shares of Synopsys common stock to be issued in the merger being approved for listing (subject to official notice of issuance) on the NASDAQ; |
• | the merger agreement being duly adopted at the special meeting by the required Ansys stockholder vote; |
• | the expiration or termination of the waiting period (and any extension thereof) applicable to the completion of the merger under the HSR Act, and any period of time (and any extension thereof) agreed to with a governmental body in the United States not to complete the merger having expired or having been terminated; |
• | the expiration or termination of any waiting period (and any extension thereof) applicable to the completion of the merger under applicable foreign antitrust law or regulation of the specified jurisdictions, and the expiration or termination of any period of time (and any extension thereof) agreed to with a governmental body in any specified jurisdiction not to complete the merger; |
• | any governmental authorization or other consent required under applicable foreign antitrust law or regulation or foreign investment law in connection with the merger in each specified jurisdiction being obtained and being in full force and effect; and |
• | no temporary restraining order, preliminary or permanent injunction or other order preventing the completion of the merger having been issued by any governmental body in any of the specified jurisdictions and remains in effect, and there having not been any legal requirement enacted or deemed applicable to the merger by any governmental body in any specified jurisdiction that makes completion of the merger illegal. |
• | solicit, initiate, knowingly encourage, assist, induce or facilitate the making, submission or announcement of any acquisition proposal or acquisition inquiry (including by approving any transaction, or approving any person or entity (other than Synopsys and its affiliates) becoming an “interested stockholder” for purposes of Section 203 of the DGCL) or take any action that would reasonably be expected to lead to an acquisition proposal or acquisition inquiry; |
• | furnish or otherwise provide access to any non-public information regarding Ansys or any of its subsidiaries to any person or entity in connection with or in response to an acquisition proposal or acquisition inquiry; |
• | engage in discussions or negotiations with any person or entity with respect to any acquisition proposal or acquisition inquiry (other than to inform such person or entity of the non-solicitation covenants in the merger agreement); |
• | approve, endorse or recommend any acquisition proposal; |
• | enter into any letter of intent, memorandum of understanding, agreement in principle or similar document or any contract relating to, or that contemplates or would reasonably be expected to result in, an acquisition transaction (other than an acceptable confidentiality agreement, as defined in “The Merger Agreement—No Solicitation by Ansys” beginning on page 101); or |
• | resolve or publicly propose to take any of the foregoing actions. |
• | withdraw or modify in a manner adverse to Synopsys, or permit the withdrawal or the modification in a manner adverse to Synopsys of, the Ansys board recommendation; |
• | recommend the approval, acceptance or adoption of, or approve, endorse, accept or adopt, any acquisition proposal; |
• | approve or recommend, or cause or permit Ansys or any of its subsidiaries to execute or enter into, any letter of intent, memorandum of understanding, agreement in principle, merger agreement, acquisition agreement, option agreement, joint venture agreement, partnership agreement or other similar document or contract relating to, or that contemplates or would reasonably be expected to result in, an acquisition transaction (other than an acceptable confidentiality agreement); or |
• | resolve, agree or publicly propose, or permit Ansys or any of its subsidiaries, or any of its or their respective representatives, to agree or publicly propose, to take any of the actions contemplated in any of the preceding bullets. |
• | by the mutual written consent of Synopsys and Ansys; |
• | by either Synopsys and Ansys if the merger has not been completed by 11:59 p.m. (California time) on the end date (as it may be extended in accordance with the merger agreement) (however, a party is not permitted to terminate the merger agreement on such basis if the failure to complete the merger by the end date is primarily attributable to a failure on the part of such party to perform any covenant or obligation in the merger agreement required to be performed by such party at or prior to the effective time in breach of such party’s obligations); |
• | by either Synopsys or Ansys if: (i) a governmental body in any specified jurisdiction has issued a final and nonappealable order having the effect of permanently restraining, enjoining or otherwise prohibiting the merger; or (ii) there has been any applicable legal requirement enacted, enforced or deemed applicable to the merger by any governmental body in any specified jurisdiction that would make completion of the merger illegal; |
• | by either Synopsys or Ansys upon a no stockholder approval event (as defined in “The Merger Agreement—Termination of the Merger Agreement” beginning on page 117); |
• | by Synopsys (at any time prior to the adoption of the merger agreement by the required Ansys stockholder vote) if a triggering event has occurred; |
• | by Ansys (at any time prior to the adoption of the merger agreement by the required Ansys stockholder vote) in order to accept a superior offer and enter into an alternative acquisition agreement, subject to compliance with certain obligations under the merger agreement; or |
• | by either Synopsys or Ansys if, subject to certain exceptions, (i) any of the other party’s representations or warranties contained in the merger agreement were inaccurate as of the date of the merger agreement or became inaccurate as of a date subsequent to the date of the merger agreement (as if made on such subsequent date) such that the closing condition relating to the accuracy of such other party’s representations and warranties would not be satisfied; or (ii) any of the other party’s covenants or obligations contained in the merger agreement was breached such that the closing condition relating to the performance by such other party of its covenants would not be satisfied. |
• | (i) by Synopsys or Ansys because the merger has not been completed by the end date (prior to the satisfaction of the stockholder approval condition (as defined in “The Merger Agreement—Conditions to the Completion of the Merger” beginning on page 114) or upon the occurrence of the no stockholder approval event; (ii) at or prior to the time of the termination of the merger agreement, but on or after the date of the merger agreement, an acquisition proposal has been publicly disclosed, announced, commenced, submitted or made and such acquisition proposal has not been publicly withdrawn at least 10 calendar days prior to the special meeting (or, in the case of a termination because the merger has not been completed by the end date, an acquisition proposal otherwise exists and has not been withdrawn); and (iii) within 12 months after the date of termination of the merger agreement, an acquisition transaction (whether or not relating to such acquisition proposal) is completed or a definitive agreement providing for an acquisition transaction (whether or not related to such acquisition proposal) is executed; provided, however, that, for purposes of clause (iii) above, all references to “15%” and “85%” in the definition of “acquisition transaction” will be deemed to be references to “50%”; or |
• | (i) by Synopsys, due to the occurrence of a triggering event; (ii) by Synopsys or Ansys, at any time after the occurrence of a triggering event, because the special meeting has been held and completed but |
• | by Synopsys or Ansys as a result of (i) a regulatory proceeding (as defined in “The Merger Agreement—Regulatory Approvals and Related Matters”) brought by a governmental body under any applicable antitrust or competition legal requirement or any applicable foreign investment law in any specified jurisdiction resulting in a final and non-appealable order having the effect of permanently restraining, enjoining or otherwise prohibiting the merger or (ii) the enactment, enforcement or deemed applicability of any legal requirement to the merger by any governmental body in a specified jurisdiction that would make the completion of the merger illegal; or |
• | by Synopsys or Ansys because the merger has not been completed by the end date and, at the time of termination, all the closing conditions set forth in the merger agreement (other than those conditions that by their terms are to be satisfied at the closing) have been satisfied or waived, other than the HSR waiting period condition, the foreign regulatory waiting period condition, the governmental authorization condition and the no restraint condition (in which case, solely in connection with any applicable antitrust law or regulation or foreign investment law in the specified jurisdictions) (each as defined in “The Merger Agreement—Conditions to Completion of the Merger” beginning on page 114). |
| | Synopsys Common Stock | | | Ansys Common Stock | | | Implied Per Share Value of Merger Consideration | |
December 21, 2023 | | | $559.96 | | | $303.16 | | | $390.19 |
January 12, 2024 | | | $494.40 | | | $346.48 | | | $367.57 |
April 9, 2024 | | | $568.99 | | | $344.50 | | | $393.30 |
• | each company may experience negative reactions from the financial markets, including negative impacts on its stock price; |
• | each company may experience negative reactions from its customers, distributors, suppliers and strategic partners; |
• | current and prospective employees of Synopsys and Ansys may experience uncertainty about their future roles with the combined company following the merger, which might adversely affect Synopsys’ or Ansys’ abilities to retain or attract key managers and other employees; |
• | each company will be required to pay their respective costs relating to the merger, such as financial advisory, legal, financing and accounting costs and associated fees and expenses, whether or not the merger is completed; |
• | the merger agreement places certain restrictions on the conduct of each company’s business before completion of the merger and such restrictions, the waiver of which is subject to the consent of the other company, which may prevent Synopsys or Ansys from taking certain other specified actions during the pendency of the merger (see the section entitled “The Merger Agreement—Interim Operations of Synopsys and Ansys” beginning on page 98 for a description of the restrictive covenants applicable to Synopsys and Ansys); and |
• | matters relating to the merger (including integration planning) will require substantial commitments of time and resources by Synopsys’ senior management and Ansys’ senior management, which otherwise could have been devoted to day-to-day operations or to other opportunities that may have been beneficial to Synopsys or Ansys, as applicable, as an independent company. |
• | solicit, initiate, knowingly encourage, assist, induce or facilitate the making, submission or announcement of any acquisition proposal or acquisition inquiry (including by approving any transaction, or approving any person (other than Synopsys and its affiliates) becoming an “interested stockholder,” for purposes of Section 203 of the DGCL) or take any action that would reasonably be expected to lead to an acquisition proposal or acquisition inquiry; |
• | furnish or otherwise provide access to any non-public information regarding Ansys or any of its subsidiaries to any person in connection with or in response to an acquisition proposal or acquisition inquiry; |
• | engage in discussions or negotiations with any person with respect to any acquisition proposal or acquisition inquiry; |
• | approve, endorse or recommend any acquisition proposal; |
• | enter into any letter of intent, memorandum of understanding, agreement in principle or similar document or any contract relating to, or that contemplates or would reasonably be expected to result in, an acquisition transaction (other than an acceptable confidentiality agreement); or |
• | resolve or publicly propose to take any of the actions described in the preceding bullets. |
• | combining the companies’ operations and corporate functions; |
• | combining the businesses of Synopsys and Ansys and meeting the capital requirements of Synopsys following the merger, in a manner that permits Synopsys to achieve any cost savings or revenue synergies anticipated to result from the merger, the failure of which would result in the anticipated benefits of the merger not being realized in the time frame currently anticipated or at all; |
• | integrating personnel and related HR systems and benefits; |
• | integrating the companies’ technologies; |
• | integrating and unifying the offerings and services available to customers; |
• | identifying and eliminating redundant and underperforming functions and assets; |
• | harmonizing the companies’ operating practices, employee development and compensation programs, internal controls and other policies, procedures and processes; |
• | maintaining existing agreements with customers, distributors, suppliers and vendors and avoiding delays in entering into new agreements with prospective customers, distributors, suppliers and vendors; |
• | addressing possible differences in business backgrounds, corporate cultures and management philosophies; |
• | consolidating the companies’ administrative and information technology infrastructure; |
• | coordinating distribution and marketing efforts; |
• | managing the movement of certain positions to different locations; |
• | coordinating geographically dispersed organizations; and |
• | effecting actions that may be required in connection with obtaining the required regulatory approvals. |
• | increasing its vulnerability to changing economic, regulatory and industry conditions; |
• | limiting its ability to compete and its flexibility in planning for, or reacting to, changes in its business and the industry; |
• | placing the combined company at a competitive disadvantage compared to its competitors with less indebtedness; |
• | limiting its ability to execute share repurchase programs; |
• | limiting its ability to borrow additional funds in the future to fund growth, acquisitions, working capital, capital expenditures and other purposes; and |
• | increasing its interest expense and potentially requiring it to dedicate a substantial portion of its cash flow from operations to payments on its debt, thereby reducing the availability of cash to available to fund its working capital and other business needs. |
• | adversely affect the trading price of, or market for, its debt securities; |
• | increase interest expense under its credit facilities; |
• | increase the cost of, and adversely affect its ability to refinance, its existing debt; and |
• | adversely affect its ability to raise additional debt. |
• | cash requirements, capital spending plans, cash flow or financial position; |
• | cash requirements for any future acquisitions; |
• | Synopsys’ stock price; |
• | Synopsys’ desire to maintain or improve the credit ratings on its debt; |
• | restrictions under Delaware law; |
• | leverage covenants in the combined company's credit facilities and indentures and, potentially, the terms of any future indebtedness that the combined company may incur; and |
• | certain limitations on the amount of dividends subsidiaries of the combined company can distribute to Synopsys, as imposed by state law, regulators or agreements. |
• | to adopt the merger agreement, which proposal is referred to as the merger agreement proposal; |
• | to approve, on a non-binding, advisory basis, the merger-related compensation that will or may be paid to Ansys’ named executive officers in connection with the transactions contemplated by the merger agreement, which proposal is referred to as the compensation proposal; and |
• | to approve the adjournment of the special meeting to solicit additional proxies if there are not sufficient votes at the time of the special meeting to approve the merger agreement proposal or to ensure that any supplement or amendment to the accompanying proxy statement/prospectus is timely provided to Ansys stockholders, which proposal is referred to as the adjournment proposal. |
• | Proposal 1: “FOR” the merger agreement proposal; |
• | Proposal 2: “FOR” the compensation proposal; and |
• | Proposal 3: “FOR” the adjournment proposal. |
Proposal | | | Votes Necessary | |||
Proposal 1 | | | Merger agreement proposal | | | Approval requires the affirmative vote of a majority of the outstanding shares of Ansys common stock entitled to vote on the merger agreement proposal. A failure to vote, a broker non-vote or an abstention will have the same effect as a vote “AGAINST” the merger agreement proposal. |
| | | | |||
Proposal 2 | | | Compensation proposal | | | Approval requires the affirmative vote of a majority of the votes cast at the special meeting on the compensation proposal (meaning the number of votes cast “FOR” this proposal must exceed the votes cast “AGAINST”). A failure to vote, a broker non-vote or an abstention will have no effect on the outcome of the compensation proposal. |
| | | | |||
Proposal 3 | | | Adjournment proposal | | | Approval requires the affirmative vote of a majority of the votes cast at the special meeting on the adjournment proposal (meaning the number of votes cast “FOR” this proposal must exceed the votes cast “AGAINST”). A failure to vote, a broker non-vote or an abstention will have no effect on the outcome of the adjournment proposal. |
• | By the Internet: If you are a stockholder of record, you can vote at www.virtualshareholdermeeting.com/ANSS2024SM and follow the instructions, 24 hours a day, seven days a week. You will need the 16-digit control number included on your proxy card or your paper voting instruction form (if you received a paper copy of the proxy materials). |
• | By Telephone: If you are a stockholder of record, you can vote using a touch-tone telephone by calling 1-800-690-6903 and follow the recorded instructions, 24 hours a day, seven days a week. You will need the 16-digit control number included on your proxy card or your paper voting instruction form (if you received a paper copy of the proxy materials). |
• | By Mail: If you have received a paper copy of the proxy materials by mail, you may complete, sign, date and return by mail the paper proxy card or voting instruction form sent to you in the envelope provided to you with your proxy materials or voting instruction form. |
• | sending a signed written notice of revocation to Ansys’ corporate secretary; |
• | voting again by the Internet or telephone at a later time before the closing of the voting facilities at 11:59 p.m., Eastern Time, on the date before the special meeting; |
• | submitting a properly signed proxy card with a later date; or |
• | attending virtually and voting at the special meeting via the special meeting website. |
• | determined that the merger agreement, the merger and the other transactions contemplated by the merger agreement are fair to, and in the best interests of, Ansys and its stockholders; |
• | approved and declared advisable the merger agreement, the merger and the other transactions contemplated by the merger agreement; |
• | directed the merger agreement be submitted for adoption at a meeting of Ansys stockholders; and |
• | recommended that Ansys stockholders vote in favor of the adoption of the merger agreement. |
• | Premium to Current Equity Price. The merger consideration to be paid by Synopsys of $197.00 in cash and 0.3450 of a share of Synopsys common stock, which implied an equity value of $390.19 per share of Ansys common stock, based on Synopsys’ closing stock price on December 21, 2023, the last full trading day prior to media speculation regarding a potential transaction, would provide Ansys stockholders with the opportunity to receive approximately (1) a 29% premium over the closing price of $303.16 per share of Ansys common stock on December 21, 2023, the last full trading day prior to media speculation regarding a potential transaction and (2) a 35% premium over the 60-day volume weighted average price for the period ending on December 21, 2023. |
• | Liquidity and Certainty of Value. A significant portion of the merger consideration to be paid to Ansys stockholders will consist of cash, which will provide immediate liquidity and certainty of value to Ansys stockholders and will mitigate the risk of any contraction in trading multiples of Synopsys stock during the pendency of the merger, and the remainder of the merger consideration to be paid to Ansys stockholders will consist of freely tradable Synopsys common stock. |
• | Future Appreciation. The merger and the merger consideration offered in connection therewith will provide Ansys stockholders with ownership of approximately 16.5% of the combined company on a pro forma basis and, therefore, allow Ansys stockholders to participate through the stock portion of the consideration in any appreciation in the equity value of Synopsys, including as a result of the synergies expected to result from the merger. |
• | Strategic Benefits. The proposed transaction provides compelling strategic and financial benefits in which Ansys stockholders would participate through the stock portion of the merger consideration, including the expectation of the Ansys board of directors that the transaction will (1) combine Synopsys’ EDA technology with Ansys’ established simulation and analysis capabilities to provide customers a comprehensive, powerful and system-focused approach to innovation, (2) combine highly complementary businesses with significant expansion opportunities, (3) build upon the successful partnership between Synopsys and Ansys dating back to 2017, (4) meaningfully expand the combined company’s total addressable market by 1.5x to $28 billion, (5) increase the combined company’s strong financial position and outlook, (6) generate substantial and sustained free cash flow for the combined company, which will enable rapid de-leveraging, (7) achieve significant cost and revenue synergies and (8) deliver greater opportunities for employee development given the larger organization. |
• | Competitive Process. The proposed transaction was the product of a competitive negotiated process that in the Ansys board of directors’ view represents the best risk-adjusted value attainable among all the parties that had put forward an indication of interest with respect to a combination with Ansys. |
• | Cultural Alignment. The cultural alignment between Ansys and Synopsys, including shared values and commitment to integrity, operational excellence, customer satisfaction, innovation and stockholder value. |
• | Synopsys’ Business Condition and Prospects. The information and discussions with Ansys’ senior management and outside advisors regarding their diligence review of Synopsys’ business, assets, financial condition, results of operations, current business strategy and prospects, including the historical operational and market performance of Synopsys, the size and scale of Synopsys and the expected pro forma effect of the proposed merger on Synopsys. |
• | Business Environment. The current and prospective business environment in which Ansys and Synopsys operate, including international, national and local economic conditions, the competitive and regulatory environment, and the likely effect of these factors on Ansys and Synopsys. |
• | Fairness Opinion. The analyses and presentations of Qatalyst Partners and its oral opinion, subsequently confirmed in writing, to the Ansys board of directors that, as of the date of the opinion, and based upon and subject to the various assumptions, qualifications, limitations and other matters set forth in its written opinion, the merger consideration to be paid to Ansys stockholders pursuant to the merger agreement was fair, from a financial point of view, to Ansys stockholders, as more fully described under the section entitled “The Merger—Opinion of Qatalyst Partners” beginning on page 72 and the full text of the written opinion of Qatalyst Partners, which is attached as Annex B to this proxy statement/prospectus. |
• | Extensive Negotiations. The merger consideration reflected extensive negotiations between Ansys and Synopsys and their respective advisors, and the belief of the Ansys board of directors that the merger consideration represents the best proposal and economic value available to Ansys’ stockholders. |
• | Regulatory Matters. The Ansys board of directors’ view, after consultation with Ansys’ senior management and Skadden, concerning the likelihood that regulatory approvals and clearances necessary to consummate the merger would be obtained. |
• | Terms of the Merger Agreement. The review by the Ansys board of directors with its advisors of the structure of the proposed merger and the financial and other terms of the merger agreement, including the parties’ representations, warranties and covenants, the conditions to their respective obligations to complete the merger and the termination provisions as well as the likelihood of consummation of the proposed transactions and the evaluation of the Ansys board of directors of the likely time period necessary to complete the merger. The Ansys board of directors also considered the following specific aspects of the merger agreement: |
○ | the limited number of closing conditions included in the merger agreement, including the absence of a financing condition or similar contingency that is based on Synopsys’ ability to obtain financing, the exceptions to the events that would constitute a material adverse effect on Ansys for purposes of the merger agreement, as well as the likelihood of satisfaction of all conditions to completion of the transactions; |
○ | the ability of Ansys stockholders to approve or reject the merger by voting on the adoption of the merger agreement; |
○ | the requirement to use reasonable best efforts to obtain approvals or clearances by applicable governmental authorities, including by divesting assets, holding assets separate or otherwise taking any other action that would limit Ansys’ or Synopsys’ freedom of action, except to the extent that such action would, individually or in the aggregate, (1) involve the divestment of businesses, product lines or assets representing, individually or in the aggregate, more than $200 million of revenue generated during fiscal year 2023 or (2) involve any limitation on the freedom of action of Synopsys, Ansys or their respective subsidiaries that would, individually or in the aggregate, reasonably be expected to have a material impact on the combined company, taken as a whole (including any impact on expected synergies), measured on a scale relative to the size of Ansys and its subsidiaries, taken as a whole, prior to the merger; |
○ | the fact that the Ansys board of directors has the right, after complying with specified covenants and prior to the Ansys stockholder approval being obtained, to change its recommendation to the Ansys stockholders that they vote in favor of the adoption of the merger agreement if the Ansys board of directors determines in good faith after consultation with Ansys’ outside legal counsel and financial advisors, that as a result of a superior proposal or certain intervening events the failure to change its recommendation would be inconsistent with its fiduciary duties to Ansys’ stockholders under applicable Delaware law; |
○ | the requirement that, in the event of the termination of the merger agreement under certain circumstances, Synopsys will pay Ansys a termination fee of $1.5 billion; and |
○ | Ansys’ right to terminate the merger agreement under certain circumstances, including in order to accept and enter into a definitive agreement with respect to an unsolicited superior offer in certain circumstances, subject to providing Synopsys an opportunity to match such offer prior to taking such action and payment to Synopsys of a termination fee of $950 million if the merger agreement is so terminated, which amount the Ansys board of directors believes to be reasonable under the circumstances, taking into account the range of such termination fees in similar transactions. |
• | the risk that Synopsys’ financial performance may not meet Ansys’ expectations, including any contraction of trading multiples of Synopsys stock during the pendency of the transaction; |
• | the impact of external factors on Synopsys’ financial performance and/or trading multiples, including changes in regulation and other macroeconomic and political factors; |
• | the difficulties and management challenges inherent in completing the merger and integrating the business, operations and workforce of Ansys and Synopsys and the risk of not capturing all the anticipated synergies and the risk that other anticipated benefits of the merger might not be realized; |
• | the amount of time it could take to complete the merger, including that completion of the merger depends on factors outside of Ansys’ or Synopsys’ control, and the risk that the pendency of the merger for an extended period of time following the announcement of the execution of the merger agreement could have an adverse impact on Ansys or Synopsys, including their respective customer, supplier and other business relationships; |
• | the possible diversion of management attention for an extended period of time during the pendency of the merger; |
• | the risk that, despite the retention efforts of Ansys and Synopsys prior to the consummation of the merger, Ansys and Synopsys may lose key personnel; |
• | the provisions of the merger agreement that prohibit Ansys from soliciting other acquisition proposals and the potential payment to Synopsys by Ansys of a termination fee of $950 million, as described in the section entitled “The Merger Agreement—Termination Fees” beginning on page 119; |
• | that certain provisions of the merger agreement, including the $950 million termination fee, may have the effect of discouraging alternative proposals to acquire Ansys; |
• | the risk that if Synopsys fails to complete the merger as a result of a breach of the merger agreement in certain circumstances, remedies may be limited to the termination fee of $1.5 billion, as described in the section entitled “The Merger Agreement—Termination Fees” beginning on page 119, which may be inadequate to compensate Ansys for the damage caused, and if available, other rights and remedies may be expensive and difficult to enforce, and the success of any such action may be uncertain; |
• | the potential for litigation relating to the proposed merger and the associated costs, burden and inconvenience involved in defending those proceedings; |
• | the restrictions in the merger agreement on the conduct of Ansys’ business during the period between execution of the merger agreement and the consummation of the merger, including that Ansys must conduct its business only in the ordinary course, subject to specific limitations, and a prohibition on Ansys entering into mergers and acquisitions, which could negatively impact Ansys’ ability to pursue certain business opportunities or strategic transactions; |
• | the risk that regulatory agencies may delay, object to and challenge the merger or may impose terms and conditions in order to resolve those objections that adversely affect the financial results of Ansys or Synopsys; see the section entitled “The Merger—Regulatory Approvals and Related Matters” beginning on page 85; |
• | the treatment of the merger consideration to be received by Ansys stockholders as taxable for U.S. federal income and other tax purposes; |
• | the fact that the exchange ratio for the stock component of the merger consideration is fixed under the merger agreement, meaning that the value of the merger consideration, consisting of $197.00 in cash and 0.3450 of a share of Synopsys common stock for each share of Ansys common stock, upon consummation of the merger might be more or less than or the same as the value of such consideration on the date of the execution of the merger agreement; and |
• |
• | adding: |
(a) | the implied net present value of the estimated future unlevered free cash flows (which are referred to as the “UFCF”) of Ansys, based on each of Management Case 1, Management Case 2 and Management Case 3, as applicable, for the calendar year 2024 through calendar year 2032 (which implied present value was calculated using a range of discount rates of 10.5% to 13.0%, based on an estimated weighted average cost of capital for Ansys); |
(b) | the implied net present value of a corresponding terminal value of Ansys, calculated by multiplying Ansys’ estimated UFCF in fiscal year 2033 of approximately $3,178 million, $2,640 million and $1,843 million, based on each of Management Case 1, Management Case 2 and Management Case 3, as applicable, by a range of fully diluted enterprise value to |
(c) | the cash and cash equivalents of Ansys as of December 31, 2023, as provided by management of Ansys, as adjusted for Ansys’ anticipated acquisition of a minority ownership interest in Humanetics Innovative Solutions, Inc.; |
• | subtracting the face value of Ansys’ outstanding debt as of December 31, 2023 (including unfunded pension obligations), as provided by Ansys’ management; and |
• | dividing the resulting amount by the number of fully diluted shares of Ansys common stock outstanding (calculated using the treasury stock method, taking into account the Ansys RSUs, Ansys PSUs, in-the-money options, and other equity awards as of January 11, 2024), as provided by management of Ansys, with each of the above-referenced estimated future UFCFs and terminal value having also been adjusted for the degree of estimated dilution to current stockholders through each respective applicable period (approximately 0.5% to 1.0% annually throughout the projection period) due to the estimated net effects of equity issuances and cancellations related to future equity compensation, based on estimates of future dilution provided by management of Ansys. |
Forecast Scenario | | | Implied Value Per Share of Ansys common stock ($) |
Management Case 1 | | | 303.33 – 496.04 |
Management Case 2 | | | 257.84 – 418.39 |
Management Case 3 | | | 160.25 – 266.24 |
Selected Engineering Software Companies | | | CY2024E LFCF Multiple |
Synopsys, Inc.(1) | | | 56.5x |
Cadence Design Systems, Inc. | | | 47.0x |
Altair Engineering Inc.(2) | | | 46.6x |
Altium Limited | | | 43.4x |
Nemetschek SE | | | 39.8x |
Bentley Systems, Incorporated | | | 39.3x |
Autodesk, Inc. | | | 36.7x |
Dassault Systèmes SE | | | 36.2x |
Aspen Technology, Inc. | | | 30.0x |
PTC Inc. | | | 27.9x |
Selected Profitable Software Companies | | | CY2024E LFCF Multiple |
ServiceNow Inc. | | | 46.3x |
Workday, Inc. | | | 38.4x |
Palo Alto Networks, Inc. | | | 36.4x |
Adobe Inc. | | | 31.3x |
SAP SE | | | 28.7x |
Oracle Corporation | | | 27.6x |
Salesforce, Inc. | | | 25.5x |
DocuSign, Inc.(3) | | | 18.5x |
ZoomInfo Technologies Inc. | | | 14.4x |
(1). | Fully diluted equity value based on per share price of $551.62, which reflects closing share price of $559.96 as of December 21, 2023, adjusted by subsequent average share price performance to January 12, 2024 of selected technical software companies including Cadence, Autodesk, PTC, Altium, Nemetschek, Bentley and Dassault. |
(2). | Fully diluted equity value reflects closing share price as of December 21, 2023, the last trading day prior to the publication of a Bloomberg article reporting on a potential sale of Ansys. |
(3). | Fully diluted equity value reflects closing share price as of December 14, 2023, the last trading day prior to rumors in the press that DocuSign was exploring a sale process. |
Equity Value / CY2024E LFCF Multiple | | | Implied Value Per Share of Ansys common stock ($) |
Management Case 1 | | | 212.98 – 340.71 |
Management Case 2 | | | 204.70 – 327.46 |
Management Case 3 | | | 198.32 – 317.24 |
Street Case | | | 210.20 – 336.26 |
Announcement Date | | | Target | | | Acquiror | | | NTM LFCF MULTIPLE |
11/14/16 | | | Mentor Graphics Corporation | | | Siemens Industry, Inc. | | | 46.6x |
08/19/21 | | | Inovalon Holdings, Inc. | | | Nordic Capital | | | 41.5x |
12/07/21 | | | Mimecast Limited | | | Permira Holdings Limited | | | 40.6x |
12/12/22 | | | Coupa Software Incorporated | | | Thoma Bravo | | | 39.3x |
12/21/20 | | | RealPage, Inc. | | | Thoma Bravo | | | 37.8x |
10/28/18 | | | Red Hat Inc. | | | IBM Corp | | | 33.8x |
09/21/22 | | | AVEVA Group plc | | | Schneider Electric SE | | | 31.9x |
09/21/23 | | | Splunk Inc. | | | Cisco Systems Inc. | | | 29.3x |
05/04/22 | | | Black Knight, Inc. | | | Intercontinental Exchange, Inc. | | | 28.2x |
03/06/18 | | | CommerceHub, Inc. | | | GTCR and Sycamore Partners | | | 26.8x |
02/02/15 | | | Advent Software, Inc. | | | SS&C Technologies Holdings, Inc. | | | 24.1x |
12/20/21 | | | Cerner Corporation | | | Oracle Corporation | | | 23.9x |
04/07/15 | | | Informatica Corp | | | Permira Holdings Limited | | | 22.1x |
09/19/16 | | | Infoblox Inc. | | | Vista Equity Partners | | | 21.9x |
06/15/15 | | | Dealertrack Technologies, Inc. | | | Cox Automotive, Inc. | | | 20.0x |
08/05/21 | | | Cornerstone OnDemand, Inc. | | | Clearlake Capital Group, L.P. | | | 18.4x |
01/31/22 | | | Citrix Systems, Inc. | | | Vista Equity Partners Management, LLC and Evergreen Coast Capital Corp. | | | 17.9x |
05/26/22 | | | VMware, Inc. | | | Broadcom Inc. | | | 16.6x |
07/01/11 | | | Blackboard Inc. | | | Providence Equity Partners L.L.C. | | | 16.2x |
12/15/14 | | | Riverbed Technology, Inc. | | | Thoma Bravo | | | 15.5x |
11/07/21 | | | McAfee Corp. | | | Advent, Permira, Crosspoint Capital, CPP Investments, GIC and ADIA | | | 14.5x |
12/17/19 | | | LogMeIn, Inc. | | | Francisco Partners Management, L.P. | | | 14.0x |
07/07/16 | | | AVG Technologies N.V. | | | Avast Software B.V. | | | 13.2x |
07/02/12 | | | Quest Software, Inc. | | | Dell Inc. | | | 12.8x |
05/06/13 | | | BMC Software Inc. | | | Bain Capital, Golden Gate Capital, GIC Special Investments Pte Ltd., and Insight Venture Partners | | | 10.6x |
11/02/15 | | | Neustar, Inc. | | | Golden Gate Capital | | | 5.9x |
06/12/19 | | | Medidata Solutions, Inc. | | | Dassault Systèmes SE | | | - |
(in millions) | | | FY2024E | | | FY2025E | | | FY2026E | | | FY2027E | | | FY2028E | | | FY2029E | | | FY2030E | | | FY2031E | | | FY2032E | | | FY2033E |
Management Case 1 | ||||||||||||||||||||||||||||||
ACV(1) | | | $2,567 | | | $2,942 | | | $3,406 | | | $3,938 | | | $4,556 | | | $5,262 | | | $6,067 | | | $6,983 | | | $8,024 | | | $9,203 |
Revenue | | | $2,510 | | | $2,890 | | | $3,367 | | | $3,892 | | | $4,503 | | | $5,201 | | | $5,997 | | | $6,902 | | | $7,931 | | | $9,097 |
Unlevered Free Cash Flow(2) | | | $795 | | | $979 | | | $1,159 | | | $1,342 | | | $1,558 | | | $1,804 | | | $2,084 | | | $2,404 | | | $2,766 | | | $3,178 |
Management Case 2 | ||||||||||||||||||||||||||||||
ACV(1) | | | $2,534 | | | $2,871 | | | $3,278 | | | $3,730 | | | $4,245 | | | $4,822 | | | $5,468 | | | $6,185 | | | $6,982 | | | $7,869 |
Revenue | | | $2,491 | | | $2,838 | | | $3,265 | | | $3,716 | | | $4,228 | | | $4,803 | | | $5,447 | | | $6,161 | | | $6,955 | | | $7,839 |
Unlevered Free Cash Flow(2) | | | $766 | | | $929 | | | $1,082 | | | $1,237 | | | $1,417 | | | $1,606 | | | $1,825 | | | $2,068 | | | $2,339 | | | $2,640 |
Management Case 3 | ||||||||||||||||||||||||||||||
ACV(1) | | | $2,508 | | | $2,767 | | | $3,054 | | | $3,332 | | | $3,615 | | | $3,897 | | | $4,182 | | | $4,466 | | | $4,747 | | | $5,027 |
Revenue | | | $2,480 | | | $2,736 | | | $3,008 | | | $3,282 | | | $3,560 | | | $3,838 | | | $4,118 | | | $4,398 | | | $4,676 | | | $4,951 |
Unlevered Free Cash Flow(2) | | | $743 | | | $881 | | | $1,005 | | | $1,115 | | | $1,229 | | | $1,346 | | | $1,466 | | | $1,589 | | | $1,716 | | | $1,843 |
(1) | Annual Contract Value (“ACV”) is a key performance metric for Ansys and is useful to investors in assessing the strength and trajectory of the business. ACV is a supplemental metric to help evaluate the annual performance of the business. Over the life of a customer, ACV equals the total value realized from a customer. ACV is not impacted by the timing of license revenue recognition. ACV is used by Ansys’ management in financial and operational decision-making and in setting sales targets used for compensation. ACV is not a replacement for, and should be viewed independently of, GAAP revenue and deferred revenue as ACV is a performance metric and is not intended to be combined with any of these items. There is no GAAP measure comparable to ACV. |
(2) | Unlevered Free Cash Flow is a supplemental non-GAAP measure used by Ansys to further evaluate performance of the business. Unlevered Free Cash Flow is calculated as unlevered operating cash flow less capital expenditures. Unlevered operating cash flow is defined as operating cash flow (a GAAP measure) excluding cash paid for interest, net of the associated tax benefit. |
• | the merger will have been completed; |
• | the absence of a material adverse effect on Ansys; |
• | the repayment and termination in full of the Ansys credit agreement; |
• | payment of fees and expenses due under the term loan credit agreement; |
• | delivery of certain historical and pro forma financial information of Synopsys and Ansys; |
• | certain specified representations and warranties under the term loan credit agreement and the merger agreement being true and correct in all material respects; and |
• | certification of the solvency of Synopsys and its subsidiaries on a consolidated basis and certain other customary documentation requirements for similar facilities. |
• | amends the applicable margin used to determine the interest that accrues on loans and the facility fee payable under the revolving credit facility to be based on the credit ratings of Synopsys; |
• | amends the financial covenant thresholds under the financial covenant in the revolving credit facility requiring us to maintain a maximum consolidated leverage ratio; and |
• | amends certain conditions to borrowing, other non-financial covenants and events of default. |